OTC Emergency Contraceptive Application Nearing FDA Panel Review
This article was originally published in The Tan Sheet
Executive Summary
Women's Capital Corporation's application to switch its Plan B emergency contraceptive from Rx to OTC status is expected to be considered by an FDA advisory panel in mid December
You may also be interested in...
Barr Plans Move To OTC Market With Plan B Emergency Contraceptive
Barr Laboratories will continue to pursue an Rx-to-OTC switch for the emergency contraceptive Plan B following its planned acquisition of the product
WCC Plan B OTC Marketing Partnership Sought Pending Switch Approval
Women's Capital Corporation "is in discussions with a number of potential strategic marketers" to sell an OTC version of its Plan B emergency contraceptive pending approval of the firm's April 21 switch application
Plan B Switch NDA Could Be Supported By New Study Findings
Study results indicating a single 1.5 mg dose of levonorgestrel is as effective as two .75 mg doses 12 hours apart could help Women's Capital Corp. in its attempt to switch its emergency contraceptive Plan B over-the-counter